Division of Infectious Diseases, The Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA.
Pediatr Infect Dis J. 2011 Nov;30(11):962-6. doi: 10.1097/INF.0b013e318232ede9.
Antiviral therapy reduces symptom duration and hospitalization risk among previously healthy and chronically ill children infected with seasonal influenza. The effect of oseltamivir on outcomes of hospitalized children is unknown. The primary objective of this study was to determine whether oseltamivir improves outcomes of critically ill children hospitalized with influenza.
We performed a retrospective cohort study of children with influenza infection admitted to a pediatric intensive care unit during 6 consecutive winter seasons (2001-2007). We used the Pediatric Health Information System database, which contains resource utilization data from 41 children's hospitals. We matched oseltamivir-treated patients with oseltamivir-nontreated patients by the probability of oseltamivir exposure using a propensity score we derived from patient and hospital characteristics. We subsequently compared the outcomes of critically ill children treated with oseltamivir within 24 hours of admission with propensity score matched children who were not treated with oseltamivir.
We identified 1257 children with influenza infection, 264 of whom were treated with oseltamivir within 24 hours of hospital admission. Multivariable analysis of 252 oseltamivir-treated patients and 252 propensity score-matched untreated patients demonstrated that patients treated with oseltamivir experienced an 18% reduction in total hospital days (time ratio: 0.82, P = 0.02), whereas intensive care unit stay, in-hospital mortality, and readmission rates did not differ.
For critically ill children infected with seasonal influenza, treatment with oseltamivir within 24 hours of hospitalization was associated with a shorter duration of hospital stay. Additional study is needed to determine the effect of delayed initiation of oseltamivir on clinical outcomes.
抗病毒疗法可缩短既往健康和慢性病患儿感染季节性流感后的症状持续时间和住院风险。奥司他韦对住院患儿结局的影响尚不清楚。本研究的主要目的是确定奥司他韦是否可改善因流感住院的危重症患儿的结局。
我们进行了一项连续 6 个冬季(2001-2007 年)期间流感感染患儿入住儿科重症监护病房的回顾性队列研究。我们使用了包含来自 41 家儿童医院的资源利用数据的儿科健康信息系统数据库。我们根据患者和医院特征推导的倾向评分,通过奥司他韦暴露概率,对奥司他韦治疗组患儿与奥司他韦未治疗组患儿进行了匹配。随后,我们比较了在入院 24 小时内接受奥司他韦治疗的危重症患儿与未接受奥司他韦治疗的经倾向评分匹配的患儿的结局。
我们共确定了 1257 例流感感染患儿,其中 264 例患儿在入院 24 小时内接受了奥司他韦治疗。对 252 例奥司他韦治疗患儿和 252 例经倾向评分匹配的未治疗患儿进行的多变量分析显示,接受奥司他韦治疗的患儿的总住院天数减少了 18%(时间比值:0.82,P=0.02),而重症监护病房停留时间、院内死亡率和再入院率无差异。
对于感染季节性流感的危重症患儿,在入院 24 小时内给予奥司他韦治疗与住院时间缩短相关。需要进一步研究来确定延迟开始奥司他韦治疗对临床结局的影响。